AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02366143
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Trial: NCT04883593
Drug: TA103
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
Trial: NCT03871049
Drug: Bupivacaine with dexamethasone
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine with dexamethasone
Trial: NCT03871049
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine
Trial: NCT00760513
Drug: OMACOR
RxNorm normalized name: Omacor
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grammes daily, oral capsule
Trial: NCT00127842
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered according to the product monograph by subcutaneous (SC) injection
Trial: NCT01053247
Drug: tacrolimus ointment 0.1%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference Product for 0416 test product. Apply twice daily for 2 weeks.
Trial: NCT00043069
Drug: Estrogen Antagonists
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00043069
Drug: risedronate sodium
RxNorm normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00564148
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Trial: NCT00486668
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
Trial: NCT04672512
Drug: CORT125329 lipid capsule formulation
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125329 lipid capsule formulation 1 or 2 for oral administration
Trial: NCT04672512
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone tablet for oral administration
Trial: NCT01864863
Drug: Traclear
RxNorm normalized name: Aluminum Zirconium Tetrachlorohydrex GLY 14.8 g in 100 g TOPICAL STICK [DEGREE ULTRACLEAR RED SATIN]
DrugBank: Aluminum zirconium tetrachlorohydrex gly (DB11149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Bosentan 62.5 mg tablets
Trial: NCT00717678
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00717678
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02061878
Drug: Bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
Trial: NCT01798186
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be exposed to cannabis smoke present in ambient air
Trial: NCT00068432
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
Trial: NCT00645177
Drug: ABT-869
RxNorm normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
Trial: NCT00645177
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
Trial: NCT00384605
Drug: taranabant
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
Trial: NCT00151918
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00504296
Drug: HDAC inhibitor SB939
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
Trial: NCT02808975
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injections administered as described in arm description
Trial: NCT00334867
Drug: dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00334867
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00334867
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00334867
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00334867
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02941068
Drug: fluconazole and caspofungin
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00557622
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
Trial: NCT02509949
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02509949
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01561482
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
Trial: NCT02045875
Drug: Dulera
RxNorm normalized name: Dulera
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
Trial: NCT03111511
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 2 mg orally on Days 1 and 21.
Trial: NCT03111511
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
Trial: NCT01458522
Drug: LCM
RxNorm normalized name: LCM
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Trial: NCT00799734
Drug: EXD
RxNorm normalized name: Aphexda
DrugBank: Motixafortide (DB14939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
Trial: NCT03251092
Drug: PTI-808
RxNorm normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT03251092
Drug: PTI-428
RxNorm normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT03251092
Drug: PTI-801
RxNorm normalized name: PTI-801
DrugBank: PTI-801 (DB05300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT00478764
Drug: intraocular triamcinolone and gatifloxicin
RxNorm normalized name: triamcinolone and antibiotics
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00195468
Drug: CYCLOSPORINE
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01479270
Drug: TAP Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
Trial: NCT01226732
Drug: Hsp90 Inhibitor AUY 922
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
Trial: NCT00942747
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
Trial: NCT00068172
Drug: PI-88
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00949377
Drug: Methylnaltrexone Bromide (MNTX)
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
Trial: NCT03125941
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-operative intravenous administration
Trial: NCT01776684
Drug: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089713
Drug: alagebrium chloride (ALT-711)
RxNorm normalized name: CHLORIDE
DrugBank: Alagebrium (DB12497)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01322438
Drug: Regorafenib (BAY73-4506) + rifampin
RxNorm normalized name: Regorafenib
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
Trial: NCT03664037
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
Trial: NCT00651443
Drug: Galiximab
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
Trial: NCT03708237
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
Trial: NCT03708237
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
Trial: NCT02833805
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
Trial: NCT02833805
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -6 through -2: 30 mg/m\^2 IV daily
Trial: NCT02833805
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start on Day 5 through Day 365
Trial: NCT02833805
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
Trial: NCT03587766
Drug: Fexinidazole
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: fexinidazole (FEXI)
Trial: NCT01551303
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.
Trial: NCT01798979
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
Trial: NCT02015988
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00701324
Drug: BI 811283
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation BI 811283, Arm B (3 weeks)
Trial: NCT00701324
Drug: BI 811283
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation BI 811283, Arm A (day 1)
Trial: NCT00701324
Drug: BI 811283
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation BI 811283, Arm A (day 15)
Trial: NCT02512510
Drug: TD-4208
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02821832
Drug: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment-standard of care
Trial: NCT00676975
Drug: Traditional Chinese Medicine
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale
Trial: NCT00234897
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00445263
Drug: TIROFIBAN
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00919204
Drug: AG-013736 (axitinib)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
Trial: NCT02523547
Drug: Cavir
RxNorm normalized name: Abacavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5mg/day
Trial: NCT02523547
Drug: Baraclude
RxNorm normalized name: Baraclude
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/day
Trial: NCT00531622
Drug: saredutant (SR48968)
RxNorm normalized name: Saredutant
DrugBank: Saredutant (DB06660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT00531622
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT00119119
Drug: tocopherol
RxNorm normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02065570
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03627611
Drug: Levothyroxin
RxNorm normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 months
Trial: NCT02094898
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg/hr of ketamine infused for 100 minutes
Trial: NCT01405794
Drug: 32ppm Silver Particle
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral silver dose of 32ppm
Trial: NCT02904291
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription amlodipine medication
Trial: NCT01432626
Drug: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
RxNorm normalized name: I 123
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
Trial: NCT01124097
Drug: Eslicarbazepine acetate (BIA 2-093)
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets will be used.
Trial: NCT00915083
Drug: Amrubicin
RxNorm normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)